Press releases and articles
07.10.18
AI/ML-based drugmaker gets FDA green light for Phase I study
Recursion plans to start study of machine learning-discovered drug REC-994 later this year, CEO says.
07.10.18
Veteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer
Recursion adds industry leader in developing and manufacturing biopharmaceuticals
07.10.18
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Up to 1.5 million individuals in the United States with CCM may be impacted
Events
05.16.18
Ron Alfa at AI in Healthcare, WPM18
Join Ron Alfa at AI in Healthcare, part of the 2018 World Precision Medicine Congress
05.22.18
Data Science Meetup: Lindsay (Anderson) Zuloaga
Please join us for our next Data Science Meetup!
Press resources
This section provides resources and assets for media partners and journalists looking for background information about Recursion Pharmaceuticals. In this section, you will find corporate descriptions, biographies of our founders, approved images, and logos. There are many stories to tell about our innovative approach to drug discovery. We welcome you to use this information as a starting point in your story development and reach out to us for interviews and specific details related to your areas of interest.
